Cytokinetics’ Failure In ALS Clears Way For Focus On Aficamten

 
• By Joseph Haas

With a data monitoring committee finding no signs of efficacy in a Phase III trial of ALS candidate reldesemtiv, Cytokinetics can conserve cash and center on aficamten for hypertrophic cardiomyopathy.

change of focus
With its ALS program shuttered, Cytokinetics will put all focus on aficamten • Source: Shutterstock

More from Clinical Trials

More from R&D